You can buy or sell AKRO and other stocks, options, and ETFs commission-free!
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA. The listed name for AKRO is Akero Therapeutics, Inc. Common Stock.
South San Francisco, California
52 Week High
52 Week Low
— per share
Expected Mar 15, After Hours